Baird Medical Showcases Cutting-Edge MWA Innovations at NASOIE 2025

New York, NY – March 3, 2025 – Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a forward-thinking medical device company specializing in AI-powered surgical robotics and next-generation surgical instruments, and a global leader in microwave ablation (MWA) technology, made a lasting impact at the 2025 North American Society of Interventional Endocrinologists (NASOIE) Annual Meeting in Lehi, Utah.

As a premier gathering for experts in interventional endocrinology, NASOIE serves as a platform for advancing minimally invasive treatments for thyroid and parathyroid disorders. The event convenes top-tier clinicians and researchers to explore the latest breakthroughs in treating thyroid nodules and cancer recurrences.

Baird Medical’s presence at NASOIE 2025 drew strong engagement, with numerous physicians visiting the booth to explore the latest advancements in MWA technology. Attendees participated in hands-on thyroid phantom demonstrations, experiencing firsthand the precision, safety, and efficiency of Baird’s technology. The Company’s experts engaged in in-depth discussions, addressing key clinical considerations and providing practical insights into MWA’s role in thyroid care. Through these interactions, Baird Medical further solidified its leadership in next-generation thyroid ablation therapies, enhancing industry awareness, and reinforcing its commitment to innovation in minimally invasive treatment solutions.

Baird Medical remains dedicated to advancing minimally invasive thyroid treatments by working closely with medical experts and industry leaders. The insights gained from NASOIE 2025 will help further refine the Company’s MWA technology, ensuring it meets the evolving needs of thyroid care. Through continued research, education, and collaboration, Baird Medical is committed to improving treatment options for patients with thyroid nodules and related conditions worldwide.